Dapagliflozin's HFpEF Benefit Recasts HF Treatment: DELIVER

Results from DELIVER made dapagliflozin the third SGLT2 inhibitor to benefit patients with HFpEF, cementing a new, ejection fraction-agnostic management approach.

Related Keywords

Boston ,Massachusetts ,United States ,Barcelona ,Comunidad Autonoma De Cataluna ,Spain ,Muthiah Vaduganathan ,Pardeeps Jhund ,Janani Rangaswami ,Frank Ruschitzka ,Katheriner Tuttle ,University Hospital ,European Society Of Cardiology ,Harvard Medical School ,University Of Glasgow ,Heart Center ,European Society ,New England Journal ,Rejection Fraction ,Heart Failure ,Cardiovascular Imaging ,Ardiac Imaging ,V Imaging ,Ejection Fraction Ef ,Eft Ventricular Ejection Fraction Lvef ,Sglt2 Inhibitors ,Odium Glucose Transporter 2 Inhibitors ,Odium Glucose Co Transporter 2 Inhibitors ,Sodium Glucose Cotransporter 2 Inhibitors ,Diabetes Mellitus Type 2 ,Iabetes Mellitus Type Ii ,Type 2 Diabetes ,Echocardiography ,Echocardiogram ,Echo ,Hospitals ,Inpat ,